## Review setup
- **Input scope** Abstract only
- **Assessment boundary** Claims and conclusions as presented in the abstract; no methods, figures, tables, or supplementary material were provided
- **Shared manuscript claim summary** The authors propose that a small molecule known to stabilize the Max homodimer (NSC13728) can also stabilize the Omomyc homodimer, based on sequence homology between Omomyc and Max. Using MD simulation and MM/GBSA free energy calculations, they report that Omomyc-Omomyc is more stable than Max-Max, that NSC13728 further increases Omomyc-Omomyc binding affinity, that NSC13728 binds more strongly to Omomyc-Omomyc than to Max-Max, and that the Omomyc "Site 3" is more hydrophobic than the corresponding Max site, suggesting hydrophobic compounds may be more potent stabilizers.
- **Visible evidence base** Abstract text only; no quantitative data, simulation parameters, convergence metrics, error estimates, or structural analyses are provided
- **Missing materials affecting confidence** Full methods, simulation setup, force field parameters, system preparation details, convergence and equilibration criteria, free energy calculation protocol, error analysis, structural figures, and any comparison with experimental data

## Reviewer
- **Overall assessment** The hypothesis is biologically plausible and clinically relevant, given the role of Myc in cancer and the potential of Omomyc as a therapeutic peptide. However, the abstract presents qualitative conclusions without any quantitative support. The central claims regarding relative stability, binding affinity enhancement, and hydrophobicity are not verifiable from the supplied material. The work may be of interest to computational biophysicists and cancer researchers, but the evidence base is insufficient to establish the case as presented.
- **Who would be interested in the results, and why** Computational chemists and biophysicists studying protein-protein interaction inhibitors, structural biologists working on Myc-Max and Omomyc systems, and cancer researchers interested in transcriptional regulation and peptide-based therapeutics. The proposed cross-targeting strategy (Max stabilizers for Omomyc) is conceptually novel and could inform drug design.
- **Major strengths** The hypothesis is clearly stated and mechanistically motivated. The study addresses a clinically relevant target (Myc) with a potentially translatable approach. The use of MD and MM/GBSA is appropriate for the stated question, and the focus on a specific binding site ("Site 3") provides a testable framework.
- **Major Concerns** 
  - R1-M1
  - R1-M2
  - R1-M3
- **Minor Comments** 
  - R1-m1
  - R1-m2
  - R1-m3
- **Technical failings that need to be addressed before the case is established** R1-M1, R1-M2, R1-M3
- **Assessment against Nature-style criteria** Originality is moderate; the cross-targeting hypothesis is novel but the approach is standard. Scientific importance is potentially high given the Myc relevance, but the abstract does not demonstrate significance beyond a computational prediction. Interdisciplinary readership is plausible but not demonstrated. Technical soundness cannot be assessed without methods and data. Readability for nonspecialists is acceptable but the lack of quantitative context limits accessibility.
- **Recommendation posture** Currently not established from the provided evidence. Supportive if the technical concerns are resolved with full data and rigorous analysis.

### Major Concerns

- **Concern ID** R1-M1
- **Severity** Major
- **Blocking** Yes
- **Axis** Evidence sufficiency
- **Claim pointer** "the stability of Omomyc-Omomyc is remarkably higher than that of Max-Max"
- **Evidence pointer** Abstract; location not provided
- **Concern** The claim of "remarkably higher" stability is made without any quantitative metric, such as free energy differences, RMSD values, or statistical significance. No error bars, standard deviations, or replicate information are provided.
- **Why it matters** Without quantitative comparison, the reader cannot judge the magnitude or reliability of the reported difference. A qualitative statement is insufficient to support a mechanistic conclusion.
- **Resolution test** Provide numerical free energy differences (e.g., MM/GBSA binding free energies) with standard errors, and show that the difference exceeds the uncertainty. Include convergence plots or replicate analyses.

- **Concern ID** R1-M2
- **Severity** Major
- **Blocking** Yes
- **Axis** Technical soundness
- **Claim pointer** "after adding the compound NSC13728 into the well-defined 'Site 3,' the binding affinity between two Omomyc monomers can be further increased"
- **Evidence pointer** Abstract; location not provided
- **Concern** The abstract does not describe how "Site 3" was defined, how the compound was placed, or how the binding affinity was calculated. MM/GBSA results are highly sensitive to the choice of dielectric model, entropy contributions, and simulation length. No validation against experimental data or known binding affinities is mentioned.
- **Why it matters** The central conclusion of the paper depends on the reliability of the free energy calculations. Without methodological detail and validation, the claim is not reproducible or verifiable.
- **Resolution test** Describe the MM/GBSA protocol in full, including entropy estimation, and validate the method against a known system. Show that the calculated binding affinity change is robust to parameter choices.

- **Concern ID** R1-M3
- **Severity** Major
- **Blocking** Yes
- **Axis** Evidence sufficiency
- **Claim pointer** "Compound NSC13728 has stronger binding interaction to Omomyc-Omomyc than to Max-Max" and "'Site 3' of Omomyc is more hydrophobic than that of Max"
- **Evidence pointer** Abstract; location not provided
- **Concern** These claims are presented as findings but no data are shown. The hydrophobicity comparison is not quantified (e.g., solvent accessible surface area, per-residue decomposition, or hydrophobicity scores). The binding interaction comparison lacks any energetic decomposition.
- **Why it matters** These claims are used to derive a design principle (hydrophobic stabilizers). Without quantitative support, the design suggestion is speculative.
- **Resolution test** Provide per-residue energy decomposition and hydrophobicity metrics with numerical values and statistical comparison between Omomyc and Max.

### Minor Comments

- **Concern ID** R1-m1
- **Severity** Minor
- **Axis** Clarity
- **Affected element** Abstract wording
- **Evidence pointer** Abstract; location not provided
- **Issue** The phrase "well-defined 'Site 3'" implies prior characterization, but no reference or definition is given in the abstract.
- **Required correction** Define "Site 3" or cite the original source where it was characterized.

- **Concern ID** R1-m2
- **Severity** Minor
- **Axis** Completeness
- **Affected element** Simulation details
- **Evidence pointer** Abstract; location not provided
- **Issue** No information is given on simulation length, force field, water model, or temperature/pressure coupling.
- **Required correction** Include these details in the abstract or state that they are in the full methods.

- **Concern ID** R1-m3
- **Severity** Minor
- **Axis** Interpretation
- **Affected element** Design implication
- **Evidence pointer** Abstract; location not provided
- **Issue** The suggestion that hydrophobic stabilizers may be more potent is presented as a conclusion, but it is only a hypothesis derived from a single compound comparison.
- **Required correction** Frame this as a testable hypothesis rather than a conclusion, and note the need for experimental validation.

## Risk / unsupported claims
- The claim that Omomyc-Omomyc stability is "remarkably higher" than Max-Max is unsupported without quantitative data.
- The claim that NSC13728 increases Omomyc-Omomyc binding affinity is unsupported without free energy values and error analysis.
- The claim that NSC13728 binds more strongly to Omomyc-Omomyc than to Max-Max is unsupported without comparative binding data.
- The claim that "Site 3" of Omomyc is more hydrophobic than that of Max is unsupported without quantitative hydrophobicity metrics.
- The design principle that hydrophobic compounds may be more potent stabilizers is speculative and not established from the provided evidence.